Efficient Synthesis and Docking Analysis of Selective CDK9 Inhibitor NVP-2

Abstract Graphical Abstract NVP-2 (1), a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9), showed potent antitumor activity in preclinical studies. In this work, we designed and adopted a convergent synthetic route to efficiently synthesize NVP-2 (1). The key intermediate (7) was synthesized from malononitrile (2) and 1-bromo-2-(2-bromoethoxy)ethane (3) by successive cyclization, reduction, nucleophilic substitution with 2-bromo-6-fluoropyridine, and Suzuki–Miyaura reaction with (5-chloro-2-fluoropyridin-4-yl)boronic acid. Another key intermediate (11) was synthesized from (S)-1-methoxypropan-2-ol (8) by reaction with TsCl, electrophilic substitution reaction with tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate, and then by deprotection of Boc. Finally, a substitution reaction by the key intermediates (7) and (11) to afford the target product NVP-2 (1). The reaction conditions of the whole synthesis process were simple and mild, free of harsh conditions such as the microwave reaction and dangerous reagents in the original patent, and realized the efficient synthesis of NVP-2. In addition, we analyzed the binding mode of NVP-2 in the active pocket of CDK9 to provide reasonable design ideas for subsequent discovery of novel CDK9 inhibitors.

[1]  Zhiyu Li,et al.  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. , 2020, Journal of medicinal chemistry.

[2]  A. Ashworth,et al.  Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. , 2020, Cancer discovery.

[3]  C. Zahnow,et al.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer , 2018, Cell.

[4]  R. Govindan,et al.  Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. , 2018, Lung cancer.

[5]  A. Giordano,et al.  CDK9: A key player in cancer and other diseases , 2018, Journal of cellular biochemistry.

[6]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[7]  Christopher J. Ott,et al.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. , 2017, Molecular cell.

[8]  L. Drew,et al.  Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models , 2016 .

[9]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[10]  C. Shapiro,et al.  Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. , 2014, Clinical breast cancer.

[11]  Patricia M. LoRusso,et al.  A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors , 2008, Investigational New Drugs.

[12]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.